TERF1 and cancer: Importantly, tankyrase, the poly(ADP-ribose) polymerase (PARP) that catalyzes TRF1 PARsylation and releases TRF1 from telomeres [86], is an emerging target for cancer therapy [87], and PARP inhibitors are in clinical trials for the treatment of cancer [88].